CCR7 -/- mice: a model for studies on early immune reponses towards alloantigens

Reference Number TO 03-00244

Challenge
Genetically modified animals are essential research tools in modern molecular biology. The chemokine receptor 7 (CCR7) is described as an important regulator of lymphocyte trafficking to and within secondary lymphoid organs, and plays a significant role in organization of the primary immune response, like e.g. in the development of transplant rejection.

Components and effects of the renin-angiotensin system.

ACE = angiotensin-converting enzyme,

AT1R = angiotensin II type 1 receptor.

Source: Medscape.com

Technology
The technology provides mice deficient in CCR7. The complex phenotype of these knock out mice is reflected by the lack of fast primary B and T cell responses. Following application of T-cell-dependent antigens, CCR7 mutant mice fail to produce specific antibodies of any IgG isotype within the first 10 days, indicating the control of a productive allospecific primary immune response by CCR7. Furthermore, in CCR7-/- mice a profound reduction in the cytotoxic T cell (CTL) response towards alloantigens can be observed, providing evidence for a defective T cell priming. The CCR7 deficiency prevents the appropriate presentation of allogeneic peptides in draining lymph nodes and results in a marked loss of allogeneic T cell priming. Overall CCR7-/- mice offer a valuable tool for studies on early immune responses and thus provide insight into diseases and clinical syndromes like e.g. allograft acceptance and rejection.

Commercial Opportunity
Breeding pairs are available under a Tangible Property License Agreement.

Patent Situation
No patent application was filed.

Further Reading
Forster et al., 1999, Cell, 99(1):23-33Höpken et al., 2004, Eur. J. Immunol., 34:461-470